LCN2 and COVID-19: In addition, our findings are consistent with a study reporting significantly higher NGAL levels in patients with COVID-19 without evidence of AKI on presentation who subsequently developed AKI stages 1 to 3 within seven days of admission, compared with those who did not develop AKI [34].